Amber Specialty Pharmacy Chosen to Dispense Aduhelm

Amber Specialty Pharmacy, a subsidiary of Hy-Vee Inc that located in Omaha, Neb., has announced that it will begin dispensing Aduhelm (aducanumab-avwa), Biogen’s and Eisai’s therapy to treat Alzheimer’s disease.

Amber Specialty Pharmacy is licensed in all 50 states, as well as Puerto Rico. “We are committed to partnering with prescribers to support caregivers, families, and patients as they navigate a devastating diagnosis like Alzheimer’s,” Kristin Williams, president of Amber Specialty Pharmacy and chief health officer of Hy-Vee, said in a statement.

Biogen and Eisai announced recently that the FDA approved updated prescribing information for Aduhelm to specify its use in patients with mild Alzheimer’s disease. Biogen officials said this was done to clarify the patient population that the therapy was studied in.